Heart and Hands Study II: A Retrospective Data Collection & Analysis Project
NCT ID: NCT02307318
Last Updated: 2017-01-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
51 participants
INTERVENTIONAL
2014-11-30
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary Objective Determine the incidence of arterial bleeding after real-world use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
Secondary Objective Determine the incidence of thrombosis at the access site in all subjects as presence of thrombus in the radial artery by reverse barbeau test; the incidence of changes in circulation, movement and sensation (CMS) in the hand and wrist on the impacted hand; and the incidence of hematoma and ecchymosis, assessed just prior to discharge.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between a Non-elastic Falcro Device and Current Method After Total Knee Arthroplasty
NCT02375945
Assessment of Radial Artery Complications Whilst Achieving Rapid Haemostasis
NCT04457219
FS VH S/D 500 S-apr in Vascular Surgery
NCT00892957
HemaTrateâ„¢ in the Treatment of Critical Limb Ischemia
NCT03809494
Fibrin Sealant Vascular Surgery Study
NCT00576420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Procedure For patients with a 4 French catheter, SoftSeal will be applied per physician instruction. Current protocol for use includes compression of ulnar artery on the same visit.
Any bleeding observed at the site after manual pressure hold with SoftSeal will constitute a failure to achieve hemostasis patient will be managed per standard of care (SOC).
Data Plan Following completion of clinical care we will extract data related to primary and secondary objectives. Data extraction will include documentation of CMS, reverse Barbeau and incidence of hematoma and ecchymosis. Any additional statistical analysis or manuscript writing will be done as part of a separate agreement to be met with the approval of both HaelaTheast Medical Research Institute and Chitogen.
Sample Size Calculation Since this is a real-world data analysis project with no control group, there is not a sample size calculation. We believe approximately 50 patients will be enough to provide an understanding of use instructions for the SoftSeal product.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SoftSeal Hemostatic Pad
This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
SoftSeal Hemostatic Pad
Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SoftSeal Hemostatic Pad
Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Prior participation in this study
* Positive standard-of-care pregnancy test
* Investigator discretionary exclusions
* Patient on dialysis
* GFR \<30
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chitogen, Inc.
INDIV
HealthEast Care System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carmelo Panetta, MD
Role: PRINCIPAL_INVESTIGATOR
HealthEast Care System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HealthEast Care System, Inc
Saint Paul, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Chit-002
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
H&H-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.